Chinese drug regulators launch safety crackdown

China's National Medical Products Administration (NMPA) has recently launched a nationwide drug safety consolidation and enhancement campaign to establish a solid foundation for drug safety.

In 2022, drug regulators across China investigated 153,600 cases of illegal and criminal acts involving drugs, cosmetics, and medical devices, a 17.65 percent increase from the previous year, said the administration. The number and quality of cases handled have increased, with many landmark and major ones cracked, effectively deterring lawbreakers and fostering a healthy drug market environment.

The drug safety campaign will last one and a half years and includes specific priority tasks.